GlaxoSmithKline on Thursday said that a pre-clinical analysis of the antibody-based COVID-19 therapy it is developing with U.S. partner Vir has indicated that the drug also works against the new Omicron variant. Read More
GSK Says Tests Show Vir Antibody Drug Works Against Omicron
